What drug is the iPLEDGE program designed to ensure safe dispensing for?

The iPLEDGE program is designed specifically to ensure the safe dispensing of isotretinoin, which is a powerful medication used to treat severe acne. The primary concern associated with isotretinoin is the risk of teratogenic effects, meaning it can cause severe birth defects if a woman becomes pregnant while taking the drug. The iPLEDGE program mandates strict protocols for prescribing, dispensing, and monitoring patients using isotretinoin to prevent these risks, especially in females of childbearing potential.

Patients enrolled in the iPLEDGE program must adhere to specific requirements, such as being on effective contraception and undergoing regular pregnancy testing to ensure safety. While Accutane is a brand name for the same active ingredient, isotretinoin, it’s important to note that the program is generally referred to by the generic drug name. Other medications listed, like finasteride and spironolactone, do have risks but are not subject to the iPLEDGE program, making isotretinoin the focus of these precautions.